Metabolomic Profiling Reveals Key Metabolic Alterations in MCF7 Tamoxifen-Resistant Cells Following EPAS1 Inhibition

This study aims to investigate the metabolic alterations associated with acquired tamoxifen (TAM) resistance in luminal A breast cancer cells. Using untargeted LC-MS/MS metabolomics, we compared parental MCF7 and TAM-resistant MCF7/Tam1 cells to identify key metabolic pathways affected by EPAS1 (HIF-2α)-mediated hypoxia-driven reprogramming. The study further evaluates the impact of EPAS1 inhibition by PT2977 on the reversal of these metabolic changes and restoration of TAM sensitivity.